{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:56:02Z","timestamp":1791244562064,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172705"],"award-info":[{"award-number":["82172705"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371745"],"award-info":[{"award-number":["82371745"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007279","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","award":["20244Y0017"],"award-info":[{"award-number":["20244Y0017"]}],"id":[{"id":"10.13039\/501100007279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007279","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","award":["202140097"],"award-info":[{"award-number":["202140097"]}],"id":[{"id":"10.13039\/501100007279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>HDAC3 is highly expressed in colorectal cancer (CRC) and associated with poor prognosis. This study reveals that HDAC3 deletion dually regulates chemokine expression through epigenetic mechanisms, promoting CD8\u207a T cell infiltration (via CXCL10) on one hand, while enhancing the recruitment of myeloid-derived suppressor cells (MDSCs) (via CXCL1\/2\/3\/5) on the other. The latter, mediated through CXCR2 signaling, counteracts the intrinsic anti-tumor effect of HDAC3 deletion. We further demonstrate that combining a CXCR2 inhibitor effectively blocks MDSC infiltration and significantly enhances the immunotherapeutic efficacy mediated by HDAC3 deletion. This study systematically elucidates the \u201cdouble-edged sword\u201d role of HDAC3 in the CRC immune microenvironment and provides a theoretical and experimental basis for an HDAC3\/CXCR2 dual-targeting therapeutic strategy.<\/jats:p>","DOI":"10.1038\/s41419-026-09006-3","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:04:44Z","timestamp":1783706684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CXCR2 blockade potentiates HDAC3 deletion mediated antitumor immunity in colorectal cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Yukun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZiHeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8650-3492","authenticated-orcid":false,"given":"Huichun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-9052","authenticated-orcid":false,"given":"Jianbin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"9006_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"9006_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41571-023-00834-2","volume":"21","author":"L Yang","year":"2024","unstructured":"Yang L, Yang J, Kleppe A, Danielsen HE, Kerr DJ. Personalizing adjuvant therapy for patients with colorectal cancer. Nat Rev Clin Oncol. 2024;21:67\u201379.","journal-title":"Nat Rev Clin Oncol"},{"key":"9006_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/stmcls\/sxae027","volume":"42","author":"AEM Larue","year":"2024","unstructured":"Larue AEM, Atlasi Y. The epigenetic landscape in intestinal stem cells and its deregulation in colorectal cancer. Stem Cells. 2024;42:509\u201325.","journal-title":"Stem Cells"},{"key":"9006_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189150","volume":"1879","author":"MD Asmamaw","year":"2024","unstructured":"Asmamaw MD, He A, Zhang LR, Liu HM, Gao Y. Histone deacetylase complexes: structure, regulation and function. Biochim Biophys Acta Rev Cancer. 2024;1879:189150.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"9006_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114065","volume":"43","author":"M Zhu","year":"2024","unstructured":"Zhu M, Han Y, Gu T, Wang R, Si X, Kong D, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024;43:114065.","journal-title":"Cell Rep"},{"key":"9006_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","volume":"10","author":"W Huang","year":"2024","unstructured":"Huang W, Zhu Q, Shi Z, Tu Y, Li Q, Zheng W, et al. Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer. Cell Death Discov. 2024;10:143.","journal-title":"Cell Death Discov"},{"key":"9006_CR7","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1158\/1078-0432.CCR-24-0796","volume":"30","author":"H Zhou","year":"2024","unstructured":"Zhou H, Qin D, Xie C, Zhou J, Jia S, Zhou Z, et al. Combinations of HDAC inhibitor and PPAR agonist induce ferroptosis of leukemic stem cell-like cells in acute myeloid leukemia. Clin Cancer Res. 2024;30:5430\u201344.","journal-title":"Clin Cancer Res"},{"key":"9006_CR8","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41418-023-01139-8","volume":"30","author":"B Dai","year":"2023","unstructured":"Dai B, Wang F, Wang Y, Zhu J, Li Y, Zhang T, et al. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARalpha. Cell Death Differ. 2023;30:1320\u201333.","journal-title":"Cell Death Differ"},{"key":"9006_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/1535-7163.MCT-18-1068","volume":"18","author":"S Deng","year":"2019","unstructured":"Deng S, Hu Q, Zhang H, Yang F, Peng C, Huang C. HDAC3 inhibition upregulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy. Mol Cancer Ther. 2019;18:900\u20138.","journal-title":"Mol Cancer Ther"},{"key":"9006_CR10","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","volume":"65","author":"S Armeanu","year":"2005","unstructured":"Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321\u20139.","journal-title":"Cancer Res"},{"key":"9006_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imm.12136","volume":"140","author":"KA Cycon","year":"2013","unstructured":"Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology. 2013;140:259\u201372.","journal-title":"Immunology"},{"key":"9006_CR12","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","volume":"81","author":"F Fan","year":"2021","unstructured":"Fan F, Liu P, Bao R, Chen J, Zhou M, Mo Z, et al. A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy. Cancer Res. 2021;81:6233\u201345.","journal-title":"Cancer Res"},{"key":"9006_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2042065","volume":"11","author":"A Bag","year":"2022","unstructured":"Bag A, Schultz A, Bhimani S, Stringfield O, Dominguez W, Mo Q, et al. Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer. Oncoimmunology. 2022;11:2042065.","journal-title":"Oncoimmunology"},{"key":"9006_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/2326-6066.CIR-22-0317","volume":"11","author":"L Li","year":"2023","unstructured":"Li L, Hao S, Gao M, Liu J, Xu X, Huang J, et al. HDAC3 inhibition promotes antitumor immunity by enhancing CXCL10-mediated chemotaxis and recruiting of immune cells. Cancer Immunol Res. 2023;11:657\u201373.","journal-title":"Cancer Immunol Res"},{"key":"9006_CR15","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1158\/0008-5472.CAN-23-3250","volume":"84","author":"J Zhu","year":"2024","unstructured":"Zhu J, Wang F, Wang L, Dai B, Xu G, Zhao L, et al. HDAC inhibition increases CXCL12 secretion to recruit natural killer cells in peripheral T-cell lymphoma. Cancer Res. 2024;84:2450\u201367.","journal-title":"Cancer Res"},{"key":"9006_CR16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317694121","volume":"121","author":"CK McGuire","year":"2024","unstructured":"McGuire CK, Meehan AS, Couser E, Bull L, Minor AC, Kuhlmann-Hogan A, et al. Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors. Proc Natl Acad Sci USA. 2024;121:e2317694121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9006_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108190","volume":"238","author":"C Brancolini","year":"2022","unstructured":"Brancolini C, Gagliano T, Minisini M. HDACs and the epigenetic plasticity of cancer cells: Target the complexity. Pharmacol Ther. 2022;238:108190.","journal-title":"Pharmacol Ther"},{"key":"9006_CR18","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6:a018713.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"9006_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-020-01720-w","volume":"39","author":"J Li","year":"2020","unstructured":"Li J, Hu M, Liu N, Li H, Yu Z, Yan Q, et al. HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p\/TGIF1\/TGFbeta axis. J Exp Clin Cancer Res. 2020;39:248.","journal-title":"J Exp Clin Cancer Res"},{"key":"9006_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.17219\/acem\/66207","volume":"27","author":"M Nemati","year":"2018","unstructured":"Nemati M, Ajami N, Estiar MA, Rezapour S, Gavgani RR, Hashemzadeh S, et al. Deregulated expression of HDAC3 in colorectal cancer and its clinical significance. Adv Clin Exp Med. 2018;27:305\u201311.","journal-title":"Adv Clin Exp Med"},{"key":"9006_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg2697","volume":"9","author":"S Han","year":"2023","unstructured":"Han S, Bao X, Zou Y, Wang L, Li Y, Yang L, et al. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci Adv. 2023;9:eadg2697.","journal-title":"Sci Adv"},{"key":"9006_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41423-024-01142-0","volume":"21","author":"R Wieboldt","year":"2024","unstructured":"Wieboldt R, Sandholzer M, Carlini E, Lin CW, Borsch A, Zingg A, et al. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2. Cell Mol Immunol. 2024;21:495\u2013509.","journal-title":"Cell Mol Immunol"},{"key":"9006_CR23","doi-asserted-by":"crossref","unstructured":"Huang Q., Tian N., Zhang J., Song S., Cheng H., Liu X., et al. Nonclassical action of Ku70 promotes Treg-suppressive function through a FOXP3-dependent mechanism in lung adenocarcinoma. J Clin Invest. 2024;134:e178079.","DOI":"10.1172\/JCI178079"},{"key":"9006_CR24","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30:1035\u201343.","journal-title":"Nat Med"},{"key":"9006_CR25","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s41564-024-01695-w","volume":"9","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wong CC, Ding Y, Gao M, Wen J, Lau HC, et al. Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice. Nat Microbiol. 2024;9:1467\u201382.","journal-title":"Nat Microbiol"},{"key":"9006_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39571-6","volume":"14","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Peng Y, Ji F, Chen H, Kang W, Chan LS, et al. Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer. Nat Commun. 2023;14:4677.","journal-title":"Nat Commun"},{"key":"9006_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1136\/gutjnl-2022-329349","volume":"72","author":"X Liu","year":"2023","unstructured":"Liu X, Tang R, Xu J, Tan Z, Liang C, Meng Q, et al. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-kappaB\/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Gut. 2023;72:2329\u201343.","journal-title":"Gut"},{"key":"9006_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019;35:559\u201372.e7.","journal-title":"Cancer Cell"},{"key":"9006_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","volume":"163","author":"H Chen","year":"2022","unstructured":"Chen H, Pan Y, Zhou Q, Liang C, Wong CC, Zhou Y, et al. METTL3 inhibits antitumor immunity by targeting m(6)A-BHLHE41-CXCL1\/CXCR2 axis to promote colorectal cancer. Gastroenterology. 2022;163:891\u2013907.","journal-title":"Gastroenterology"},{"key":"9006_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1053\/j.gastro.2024.02.046","volume":"167","author":"Y Xie","year":"2024","unstructured":"Xie Y, Zhou T, Li X, Zhao K, Bai W, Hou X, et al. Targeting ESE3\/EHF with nifurtimox inhibits CXCR2(+) neutrophil infiltration and overcomes pancreatic cancer resistance to chemotherapy and immunotherapy. Gastroenterology. 2024;167:281\u201397.","journal-title":"Gastroenterology"},{"key":"9006_CR31","doi-asserted-by":"publisher","first-page":"21931","DOI":"10.1073\/pnas.1016071107","volume":"107","author":"MP Creyghton","year":"2010","unstructured":"Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci USA. 2010;107:21931\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9006_CR32","first-page":"3034","volume":"12","author":"C He","year":"2022","unstructured":"He C, He L, Lu Q, Xiao J, Dong W. The functions and prognostic values of chemokine and chemokine receptors in gastric cancer. Am J Cancer Res. 2022;12:3034\u201350.","journal-title":"Am J Cancer Res"},{"key":"9006_CR33","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1111\/bph.12844","volume":"172","author":"L Simo-Riudalbas","year":"2015","unstructured":"Simo-Riudalbas L, Esteller M. Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol. 2015;172:2716\u201332.","journal-title":"Br J Pharmacol"},{"key":"9006_CR34","first-page":"664","volume":"6","author":"L Lutz","year":"2016","unstructured":"Lutz L, Fitzner IC, Ahrens T, Geissler AL, Makowiec F, Hopt UT, et al. Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro. Am J Cancer Res. 2016;6:664\u201376.","journal-title":"Am J Cancer Res"},{"key":"9006_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/DDDT.S234871","volume":"14","author":"X Yu","year":"2020","unstructured":"Yu X, Yang F, Jiang H, Fan L. RGFP966 suppresses tumor growth and migration through inhibition of EGFR expression in hepatocellular carcinoma cells in vitro. Drug Des Devel Ther. 2020;14:121\u20138.","journal-title":"Drug Des Devel Ther"},{"key":"9006_CR36","doi-asserted-by":"crossref","unstructured":"Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med. 2018;10:e8478.","DOI":"10.15252\/emmm.201708478"},{"key":"9006_CR37","doi-asserted-by":"crossref","unstructured":"Korbecki J, Bosiacki M, Chlubek D, Baranowska-Bosiacka I. Bioinformatic analysis of the CXCR2 ligands in cancer processes. Int J Mol Sci. 2023;24:13287.","DOI":"10.3390\/ijms241713287"},{"key":"9006_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21:184.","journal-title":"Mol Cancer"},{"key":"9006_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00280-018-3721-6","volume":"83","author":"A Keremu","year":"2019","unstructured":"Keremu A, Aimaiti A, Liang Z, Zou X. Role of the HDAC6\/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. Cancer Chemother Pharmacol. 2019;83:255\u201364.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09006-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:27:49Z","timestamp":1791242869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09006-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9006"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09006-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Huashan hospital, Fudan University (ID: 2021JSHuashanhospital-270). Written informed consent was acquired from each patient before participation in this study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"862"}}